CEBPD and glioblastoma: Before pursuing one of the 18 identified compounds that suppress C/EBPδ in, for instance, glioblastoma, urothelial bladder cancer or the acute inflammatory response, one should realise that compounds modifying C/EBPδ in HEK cells may also not regulate C/EBPδ in other cell types.